Measuring dry eye symptoms in patients receiving anti-VEGF injections
Single-center Study Measuring OSDI Dry Eye Score in Patients Undergoing an Anti-VEGF Induction Protocol
This study is trying to see how anti-VEGF eye injections affect dry eye symptoms in people being treated for macular degeneration or other eye conditions.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 50 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Clermont-Ferrand Academic / other |
| Locations | 1 site (Clermont-Ferrand) |
| Trial ID | NCT06262737 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the sensation of dry eye symptoms in patients undergoing treatment for macular degeneration, diabetic macular edema, or retinal vein occlusion after receiving intravitreal injections of anti-VEGF. Patients will be recruited by nurses and confirmed by an ophthalmologist at the University Hospital of Clermont-Ferrand. The study involves measuring the Ocular Surface Disease Index (OSDI) before each injection and at specified intervals afterward, alongside clinical assessments of tear production and meibomian gland health.
Who should consider this trial
Good fit: Ideal candidates are patients with exudative age-related macular degeneration, diabetic macular edema, or retinal vein occlusion who are scheduled for three ocular intravitreal injections of anti-VEGF in one eye.
Not a fit: Patients who are pregnant, breastfeeding, or have had prior intravitreal injections in both eyes will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could help improve the management of dry eye symptoms in patients receiving anti-VEGF treatments.
How similar studies have performed: While the specific approach of measuring dry eye symptoms post-injection may be novel, similar studies have explored ocular symptoms in patients receiving anti-VEGF treatments.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient with exsudative age-related macular degeneration, diabetic macular edema or retinal vein occlusion * Patient with 3 ocular intravitreal injections of anti-VEGF in one eye Exclusion Criteria: * pregnant or breastfeeding woman * intravitreal injection before the study * intravitreal injection in both eyes * allergy of betadine * guardianship patient
Where this trial is running
Clermont-Ferrand
- CHU de Clermont-Ferrand — Clermont-Ferrand, France (Recruiting)
Study contacts
- Principal investigator: Frederic CHIAMBARETTA — University Hospital, Clermont-Ferrand
- Study coordinator: Lise LACLAUTRE
- Email: promo_interne_drci@chu-clermontferrand.fr
- Phone: +33473754963
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.